A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.

Chandramohan, VidyalakshmiBigner, Darell D2022-09-012022-09-012013-122162-40112162-402Xhttps://hdl.handle.net/10161/25631Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (<i>EGFR</i>) and the overexpression of the <i>EGFR</i> deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas.Pseudomonasexotoxinbispecific antibodybrain tumorsconvection-enhanced deliveryglioma-associated antigensA novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.Journal article2022-09-01